Family members of a Texas man who died after a delayed COPD medication highlighted how prior‑authorization requirements can turn a routine prescription into a life‑or‑death issue.
Letter details the tragic timeline
In a letter submitted to a newspaper, Cindy Clements Blewett recounted that her husband, Kenney, a 78‑year‑old chronic obstructive pulmonary disease patient, was prescribed two nebulizer treatments on June 2. One medication arrived directly from the drug maker, but the second required a prior‑authorization request from his health insurer.
Blewett said the pharmacy called the physician’s office to start the authorization, yet the doctor never completed the paperwork.
By June 7, the request was still pending, and the medication remained unfilled. On that Sunday, Kenney experienced a severe flare‑up while his wife was mowing the lawn, and he later took his own life, leaving a note that expressed hopelessness over the uncertainty of breathing.
Related: Missouri Considers Tax on Medical Care
The “welcome” packet for the delayed treatment finally arrived 25 days after the prescription, highlighting the lengthy bureaucratic lag. Blewett suggested that timely access to both drugs might have prevented the fatal outcome, emphasizing the emotional toll of insurance hurdles on patients and families.
Broader concerns about prior‑authorization practices
Prior‑authorization policies are intended to curb wasteful spending, but critics argue they can obstruct essential care. The Centers for Medicare & Medicaid Services have reported that such requirements add administrative burdens to clinicians, often delaying treatment for vulnerable patients. In Kenney’s case, the delay coincided with an acute COPD exacerbation, a condition that can rapidly deteriorate without prompt therapy.
Health insurers typically require physicians to justify the medical necessity of a drug, even when a specialist has already prescribed it. Pharmacists, who are often the first point of contact, may be unable to expedite the process without direct input from the prescribing clinician. This layered approval system can create gaps, especially when patients or caregivers are not present to advocate for immediate action.
Blewett’s account reflects a larger pattern where patients with chronic illnesses face similar obstacles. A 2023 study found that nearly 30 % of patients with respiratory diseases experienced at least one medication delay due to prior‑authorization, and many reported increased anxiety and reduced adherence.
Related: Knee Surgery Not Always Best Option
While insurers argue that prior‑authorization helps prevent unnecessary spending, the human cost can be severe. The emotional strain described in the letter—fear of not being able to breathe, isolation, and the ultimate decision to end one’s life—illustrates the potential consequences of a system that may prioritize cost control over patient safety.
Healthcare policymakers have begun to examine these issues. Some states are considering legislation to limit prior‑authorization for life‑saving drugs, and the Department of Health and Human Services has issued guidance encouraging faster turnaround times. The ongoing debate highlights the need to balance fiscal responsibility with the imperative to provide uninterrupted care.
For families like the Blewetts, the loss is irreversible. Their story adds a personal dimension to a policy discussion that often relies on abstract numbers, reminding readers that behind each statistic is a real person facing a critical health decision.
